Jefferies Reaffirms a Buy Rating on GSK plc (GSK) - Here's Why

GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc (NYSE:GSK) on January 7 and set a price target of $55.60. The same day, GSK plc (NYSE:GSK) announced that the European Commission approved Shingrix, its Recombinant Zoster Vaccine or RZV, in a prefilled syringe.

The vaccine presentation currently includes two vials, one with a lyophilised powder antigen and another with a liquid adjuvant, with the lyophilised powder antigen requiring reconstitution. The suspension in the adjuvant vial is withdrawn and injected into the antigen vial. However, the new prefilled syringe simplifies the vaccine administration process for healthcare professionals as it eliminates the requirement to follow these steps before administration.

Tony Wood, Chief Scientific Officer, GSK plc (NYSE:GSK), stated that the new presentation of Shingrix is specially designed to ease administration, allowing healthcare professionals to deliver improved protection against shingles, a painful disease that can have serious and long-lasting complications.

Management further reported that the approval is based on data confirming technical comparability between the prefilled syringe and the existing vaccine presentation, and that the new presentation does not include a change in indication or dosing.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global biopharma company that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, among others.

While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.